Novel combinations are also arising, including the anti-PD-1/interleukin-2 (IL-2) bsAb fusion protein, IBI363, that achieves simultaneous PD-1 blockade and IL-2 delivery for melanoma treatment. Here, IL2 is linked to melanoma.